Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Monoclonal Antibodies Obesity Treatments Alzheimer's Disease Combination Therapy Eli Lilly Novo Nordisk GLP-1 Drugs Immunotherapy Obesity Treatment

FDA Approves Auvelity, the First Non‑Antipsychotic for Alzheimer’s Agitation

The decision offers an alternative to drugs that carry boxed mortality warnings.

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

Eli Lilly Posts Big Q1 Beat, Raises 2026 Outlook on GLP-1 Demand

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Canada Approves First Generic Ozempic, Clearing Dr. Reddy’s Semaglutide

Stories older than 24h

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

WHO Prequalifies First Malaria Treatment for Newborns

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

EU Drug Panel Backs Sanofi’s Cenrifki for Non‑Relapsing SPMS

KRAS Pill Doubles Survival in Trial as Pancreatic Cancer Vaccine Advances

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

Roche Files MS Drug Fenebrutinib With Regulators Despite Trial Deaths

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer